Profile
DIMITRA KANALOUPITI
MEDICAL ONCOLOGIST
DIRECTOR-4TH ONCOLOGY CLINIC
- General
-
Education & Academic Titles
- Certification in Medical Oncology by the American Board of Internal Medicine (ABIM), U.S.A
- Certification in Hematology by the ABIM, U.S.A
- Certification in Internal Medicine by the ABIM, U.S.A
- Medical Oncology/Hematology Fellowship, Advocate Lutheran General Hospital (ALGH), Park Ridge/Chicago, U.S.A
- Internal Medicine Residency, Rush St. Luke’s Hospital/Rush University, Chicago, U.S.A
- Doctor of Medicine/Medical Degree, Rush Medical College/Rush University, Chicago, U.S.A
- Bachelor of Science in Biological Sciences/Biology (Magna cum Laude), Loyola University of Chicago, Chicago, U.S.A
-
Professional Experience
- Attending/Consultant in Medical Oncology/Hematology, Advocate Medical Group, Advocate Lutheran General Hospital (ALGH), Park Ridge/Chicago, USA
- Assistant Director, 1st Oncology Clinic, Metropolitan Hospital, Athens, Greece
- Physician Coordinator of Supportive Care Program, 1st Oncology Clinic, Metropolitan Hospital, Athens, Greece
-
Clinical Interests
- Diagnosis and treatment of all solid tumors
- Specialized in Breast cancer, Gynecological cancer and Melanoma
- Supportive and Palliative Care
- Survivorship
-
Awards & Distinctions
- Humanitarian Award (Melanoma Research Foundation), Advocate Lutheran General Hospital Physicians, 5th Annual Chicago Gala, U.S.A
- Cancer Expert Now (CEN) Global Expert Panelist
- “Fellow of the Year”, Department of Medicine, ALGH, Chicagο, U.S.A
- Alpha Sigma Nu (ΑΣΝ) National Honor Society
- Golden Key National Honor Society
- Phi Beta Kappa (ΦΒΚ) Honor Society
- Magna Cum Laude Distinction
- Dean’s List
- Presidential Scholarship
-
Publications
- “Acute Myeloid Leukemia with t(4;12)(q12;p13) treated with an Allogeneic Stem Cell Transplant: A case report and review of the literature”. Leukemia Research Reports, 2018 May; 9:76-78. Hancock C, Kanaloupitis D, et al.
- “Safety and efficacy of concurrent administration of influenza vaccine in patients undergoing anti-PD-1 immunotherapy”. Journal of Clinical Oncology 35, 2017 (suppl; abstr e14607). Kanaloupitis D, Chandran A, et al.
- “The Dying Patient”. I Drasis mas. 2011 Jan. Kanaloupiti D, Michalakopoulou P.
- “Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer”. Lancet Oncology. 2008 Oct; 9(10): 962-972. Cited in PubMed; PMID: 18804418. Linardou H, Dahabreh IJ, Kanaloupiti D, et al.
- “Predisposing factors for critical illness polyneuromyopathy in a multidisciplinary intensive care unit”. Acta Neurol Scandinavica. 2008 Sep; 118(3): 175-181. Cited in PubMed; PMID: 18355395. Nanas S, Kritikos K, Angelopoulos E, Siafaka A, Tsikriki S, Poriazi M, Kanaloupiti D, et al.
- “Gastrointestinal solitary metastases from squamous cell lung cancer”. Lung Cancer. 2007 Feb; 55(2): 251-252. Cited In PubMed; PMID: 17113186. Karamouzis MV, Linardou H, Papadopoulos G, Bousboukea E, Kanaloupiti D., et al.
- Propofol-induced hyperamylasaemia in a general intensive care unit”. Anaesth Intensive Care. 2007 Dec; 35(6): 920-923. Nanas S, Angelopoulos E, Tsikriki S, Kritikos K, Voutsinas E, Zervakis D, Kanaloupiti D, et al.
-
Membership in Societies and Editorial Boards
- American Society of Clinical Oncology (ASCO)
- Hellenic Society of Medical Oncology (HeSMO)
- Cancer Expert Now – Global Expert Panelist
- Mediterranean Multidisciplinary Oncology Forum (ΜΜOF)
- Medical Society of Athens
- Multidisciplinary Breast Tumor Board, Advocate Lutheran General Hospital (ALGH), U.S.A
- Multidisciplinary Gynecologic Oncology Tumor Board, ALGH, U.S.A
- Melanoma Clinic, ALGH, U.S.A
-
Research
- “A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects with Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN (Amgen 20170758)”. Site #1815.
- “Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)”. Site #0025
- “Pattern of use and safety/effectiveness of Nivolumab in routine oncology practice”. Study No. CA209234
- “Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy”. IRB No. 6443.
- “Incidence of Bone Fracture Occurrence and Evaluation of Pain Control in Cancer Patients with Bone Metastases Treated with Zolendronic Acid Monthly Intravenous Infusion: An Epidemiologic/ Observation Study”.